There is no proposal to introduce TB drug Bedaquiline in the Indian market, parliament was told Tuesday.
"No application under the Drugs and Cosmetic Rules has been received by the Drug Controller General (of India) for the grant of permission to market the drug," Health Minister Ghulam Nabi Azad told the Rajya Sabha in reply to a question.
A new drug can only be introduced in the Indian market after due approval from the Drug Controller General of India (DCGI).
The prevalence of TB cases in the country is showing a declining trend. The estimated prevalence of TB has been brought down from 586 per lakh (1,00,000) population (1990) to 249 per lakh population in 2009, according to the WHO global report 2010.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app